tiprankstipranks
Blurbs

Biolinerx (BLRX) Receives a Buy from H.C. Wainwright

H.C. Wainwright analyst Joseph Pantginis reiterated a Buy rating on Biolinerx (BLRXResearch Report) today and set a price target of $19.00. The company’s shares closed last Tuesday at $2.01, close to its 52-week low of $1.93.

According to TipRanks.com, Pantginis ‘ ranking currently consits of 0 on a 0-5 ranking scale, with an average return of -13.7% and a 24.5% success rate. Pantginis covers the Healthcare sector, focusing on stocks such as Applied Genetic Technologies, Lineage Cell Therapeutics, and Actinium Pharmaceuticals.

The word on The Street in general, suggests a Hold analyst consensus rating for Biolinerx.

See the top stocks recommended by analysts >>

Biolinerx’s market cap is currently $97.5M and has a P/E ratio of -1.73.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

BioLineRx Ltd. is a clinical-stage biopharmaceutical company, which includes indentifying, in-licensing, and developing therapeutic candidates. Its in-licenses novel compounds, primarily from academic institutions and biotech companies based in Israel, and develops them through pre-clinical and clinical stages, and then partners with pharmaceutical companies clinical development and commercialization. The company was founded in April 2003 and is headquartered in Modi’in, Israel.

Read More on BLRX:

Tired of arriving late to the Big Returns Party?​
Most investors don’t have major gainers like TSLA or NVDA on their radar from the start.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype.
​​For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate.​
Learn More
Videos
---

Latest News Feed